<DOC>
	<DOCNO>NCT00042809</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine erlotinib trastuzumab paclitaxel treat patient advance solid tumor . Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining erlotinib trastuzumab paclitaxel may kill tumor cell</brief_summary>
	<brief_title>Erlotinib , Trastuzumab , Paclitaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , quantitative qualitative toxic effect , maximum tolerate dose , dose-limiting toxic effect erlotinib combine paclitaxel trastuzumab ( Herceptin ) patient advance solid tumor . II . Determine relevant pharmacokinetic interaction agent patient . III . Determine , preliminarily , antitumor activity regimen patient . OUTLINE : This open-label , non-randomized , multicenter , dose-escalation study erlotinib . Intermittent schedule : Patients receive paclitaxel IV 1 hour follow 30 minute later trastuzumab ( Herceptin ) IV 30 minute day 1 , 8 , 15 course . Patients also receive oral erlotinib daily day 3-28 course 1 day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Continuous schedule : Once MTD determine use intermittent schedule , additional 12 patient accrue study tolerability continuous schedule comprise paclitaxel trastuzumab day 1 , 8 , 15 , 22 oral erlotinib daily day 3-28 course 1 day 1-28 subsequent course use dose-escalation scheme . Courses repeat . Patients follow every 30 day . PROJECTED ACCRUAL : A maximum 40 patient accrue study within 10-13.3 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm metastatic solid tumor effective standard treatment option HER2 positive ( 1+ 3+ ) Tumor high likelihood express epidermal growth factor receptor ( EGFR ) No evidence leptomeningeal disease brain metastases unless previously treat , currently asymptomatic , antiepileptic dexamethasone Patients treat brain metastasis eligible without clinical change brain disease status least 4 week whole brain irradiation Performance status ECOG 02 Performance status Karnofsky 60100 % At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver tumor involvement ) Creatinine normal Creatinine clearance least 60 mL/min LVEF 50 % radionuclide ventriculogram MUGA scan No significant cardiovascular disease No prior congestive heart failure require therapy No unstable angina pectoris No myocardial infarction within past 6 month No gastrointestinal tract disease result inability take oral medication requirement IV alimentation Patients unable swallow tablet and/or siliconbased Gtubes may dissolve tablet distilled water No active peptic ulcer disease HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known suspect hypersensitivity paclitaxel No prior allergic reaction attribute compound similar chemical biologic composition erlotinib study agents No concurrent active infection No concurrent medical condition would preclude study participation No persistent grade 2 great neurotoxicity/neuropathy cause No psychiatric disorder alter mental status would preclude study participation No concurrent immunotherapy No concurrent cytokine growth factor ( e.g. , colonystimulating factor ) At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy See Disease Characteristics No concurrent hormonal therapy except megestrol appetite stimulant luteinizing hormonereleasing hormone agonist prostate cancer See Disease Characteristics No concurrent radiotherapy No prior surgical procedure affect absorption No prior EGFRtargeting therapy No concurrent experimental medication specific antitumor therapy No concurrent immunosuppressant therapy No concurrent antiarrhythmic therapy ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>